Navigation Links
Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013
Date:5/20/2013

therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  Any statements in this release that are not historical facts may be considered "forward-looking statements".  Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; growth strategies; timing and achievement of product development milestones; outcome of ongoing litigation; the impact and benefits of market development; product introductions; unexpected new data, safety and technical issues; market conditions; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... - Phase 2 trial expected to begin in late ... June 4 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... a,single-center, Phase 1b trial to determine the safety, tolerability ... direct,thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers., ...
... at American Society of Clinical Oncology meeting indicate ... compared to historical data., PRINCETON, N.J., June ... CPX-1 Phase 2 clinical trial in patients,with advanced ... and floxuridine, based on the company,s proprietary,CombiPlex(TM) technology. ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Programs, with accountability for overall performance of the company’s Medicare and Federal Employee ... of Cambia’s strategy to deliver better health for members. In this role, Scott ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... provider of medical information, risk management and investigative services, has introduced a ... toward focused, expert information solutions that improve business outcomes for its customers. ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Did you ... or Orange County looking for exceptional and affordable home care options which A-1 Home ... are just a few of the credentials A-1 Home Care Agency is ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3
... Niche, Healthcare-Career Site Recognized by Candidate Community , ... ... onTargetjobs Inc. (OTJ) company and North America,s premier healthcare ... named as this year,s top job sites., , , , ,"With ...
... 3 Though one in three women in this country ... receiving the same in-hospital treatment that men do for heart ... die. (Please copy and paste the following link into your ... a big concern. For example, women are 14% less likely ...
... Feb. 3 ETHEX Corporation, a subsidiary of KV ... nationwide recall of the products identified below (all lots ... The Company is taking this action as a precautionary ... conditions that did not sufficiently comply with current Good ...
... Feb. 3 Brent McKenzie, based in ... the nation,s fastest growing,pharmacy benefit firm, as ... Mr. McKenzie offers his clients over 25 ... and Pharmacy Benefit Management arena.,Brent has worked ...
... products containing nanomaterials must immediately institute high-quality risk ... liability exposure in the future, assert attorneys Jesse ... be thoroughly explored at FDLI,s 2nd Annual Conference ... 2009, in Washington, D.C., and discussed in a ...
... 2009) Green tea products have become regarded as ... of its benefit against a variety of diseases, including ... green tea may counteract the anticancer effects of one ... be contraindicated for patients taking this medicine to ensure its ...
Cached Medicine News:Health News:HEALTHeCAREERS Network Receives WEDDLE's 2009 User's Choice Award 2Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 2Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 3Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:Risk-Management Policies Needed Now in Nanotechnology, Insighter Piece Concludes; FDLI Sponsors Nanotechnology Meeting, Publishes Book on FDA-Regulated Products 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: